PDF(Pubmed)
Abstract：
UNASSIGNED: The coronavirus disease 2019 (COVID-19) pandemic has limited healthcare delivery for patients with chronic diseases, including Systemic Lupus Erythematosus (SLE). This study aims to describe the outcomes of patients with SLE in a national COVID-19 referral center in the Philippines.
UNASSIGNED: A review of records of all adult patients with SLE seen in the University of the Philippines-Philippine General Hospital (UP-PGH) from March 2020 to December 2021 was done. Data about patient characteristics, health encounters, and outcomes before and after the first visit during the study period were extracted. Descriptive statistics were employed.
UNASSIGNED: Our population of 403 patients was predominantly young (mean age 34.53 ± 11.14 years), female, and unemployed. This consisted of 370 known cases of SLE, 92 were diagnosed in institutions outside UP-PGH, and 33 new patients. Over the 22-month study period, there were 2,093 medical encounters, most of which were teleconsultations (81.70%). During an average gap of 53.6 ± 26.7 weeks between the last consultation and the first visit within the pandemic study period, 84 patients (22.70%) discontinued at least one of their SLE control medications, 68 (18.38%) patients developed a lupus flare, and 79 (21.35%) were hospitalized for various reasons. On their return to the rheumatology clinic during the pandemic, 37.47% were in lupus flare, 28.29% needed to be hospitalized, and 20 died. However, 86.75% of flares were controlled. During subsequent health encounters, 48 patients had a new flare (43 of these were controlled) and 20 died. The most common reason for hospitalization (n=160) was lupus disease flare and the most common cause of death (n=40) was pneumonia. Sixty patients acquired COVID-19 infection from which most recovered and four died.
UNASSIGNED: Audio teleconsultation was the most common method used by our lupus cohort to interact with their doctors during the pandemic. There was an average of a year-long interruption in medical care for 62.70%. More than a third developed a disease flare and 15% acquired COVID-19 but outcomes were good in more than 85%. Despite the challenges posed by the pandemic, the majority of our lupus cohort who were able to continue their treatment had favorable outcomes.
UNASSIGNED: A review of records of all adult patients with SLE seen in the University of the Philippines-Philippine General Hospital (UP-PGH) from March 2020 to December 2021 was done. Data about patient characteristics, health encounters, and outcomes before and after the first visit during the study period were extracted. Descriptive statistics were employed.
UNASSIGNED: Our population of 403 patients was predominantly young (mean age 34.53 ± 11.14 years), female, and unemployed. This consisted of 370 known cases of SLE, 92 were diagnosed in institutions outside UP-PGH, and 33 new patients. Over the 22-month study period, there were 2,093 medical encounters, most of which were teleconsultations (81.70%). During an average gap of 53.6 ± 26.7 weeks between the last consultation and the first visit within the pandemic study period, 84 patients (22.70%) discontinued at least one of their SLE control medications, 68 (18.38%) patients developed a lupus flare, and 79 (21.35%) were hospitalized for various reasons. On their return to the rheumatology clinic during the pandemic, 37.47% were in lupus flare, 28.29% needed to be hospitalized, and 20 died. However, 86.75% of flares were controlled. During subsequent health encounters, 48 patients had a new flare (43 of these were controlled) and 20 died. The most common reason for hospitalization (n=160) was lupus disease flare and the most common cause of death (n=40) was pneumonia. Sixty patients acquired COVID-19 infection from which most recovered and four died.
UNASSIGNED: Audio teleconsultation was the most common method used by our lupus cohort to interact with their doctors during the pandemic. There was an average of a year-long interruption in medical care for 62.70%. More than a third developed a disease flare and 15% acquired COVID-19 but outcomes were good in more than 85%. Despite the challenges posed by the pandemic, the majority of our lupus cohort who were able to continue their treatment had favorable outcomes.
摘要：
■2019年冠状病毒病（COVID-19）大流行限制了慢性病患者的医疗保健服务，包括系统性红斑狼疮（SLE）。这项研究旨在描述菲律宾国家COVID-19转诊中心的SLE患者的预后。
■对2020年3月至2021年12月在菲律宾大学-菲律宾总医院（UP-PGH）看到的所有成人SLE患者的记录进行了回顾。有关患者特征的数据，健康遭遇，并提取研究期间首次访视前后的结局.采用描述性统计数据。
■我们的403名患者主要是年轻人（平均年龄34.53±11.14岁），女性,和失业。这包括370例已知的SLE，92人在UP-PGH以外的机构被诊断出，33个新病人在22个月的研究期间，有2093次医疗遭遇，其中大部分是远程会诊(81.70%)。在大流行研究期间的最后一次咨询和首次访问之间的平均间隔为53.6±26.7周，84名患者（22.70%）停用了至少一种SLE控制药物，68例（18.38%）患者出现狼疮发作，79例(21.35%)因各种原因住院。大流行期间他们回到风湿病诊所后，37.47%的人出现狼疮发作,28.29%需要住院，20人死亡。然而,86.75%的耀斑得到控制。在随后的健康遭遇中，48例患者出现新的发作（其中43例得到控制），20例死亡。住院的最常见原因（n=160）是狼疮疾病发作，最常见的死亡原因（n=40）是肺炎。60例患者感染了COVID-19，其中大部分康复，4例死亡。
音频远程会诊是我们的狼疮队列在大流行期间与医生互动的最常用方法。平均有62.70％的医疗服务中断一年。超过三分之一的人出现了疾病发作，15%的人获得了COVID-19，但85%以上的人的结果良好。尽管大流行带来了挑战，在我们的狼疮队列中,大多数能够继续治疗的患者均获得了良好的结局.
■对2020年3月至2021年12月在菲律宾大学-菲律宾总医院（UP-PGH）看到的所有成人SLE患者的记录进行了回顾。有关患者特征的数据，健康遭遇，并提取研究期间首次访视前后的结局.采用描述性统计数据。
■我们的403名患者主要是年轻人（平均年龄34.53±11.14岁），女性,和失业。这包括370例已知的SLE，92人在UP-PGH以外的机构被诊断出，33个新病人在22个月的研究期间，有2093次医疗遭遇，其中大部分是远程会诊(81.70%)。在大流行研究期间的最后一次咨询和首次访问之间的平均间隔为53.6±26.7周，84名患者（22.70%）停用了至少一种SLE控制药物，68例（18.38%）患者出现狼疮发作，79例(21.35%)因各种原因住院。大流行期间他们回到风湿病诊所后，37.47%的人出现狼疮发作,28.29%需要住院，20人死亡。然而,86.75%的耀斑得到控制。在随后的健康遭遇中，48例患者出现新的发作（其中43例得到控制），20例死亡。住院的最常见原因（n=160）是狼疮疾病发作，最常见的死亡原因（n=40）是肺炎。60例患者感染了COVID-19，其中大部分康复，4例死亡。
音频远程会诊是我们的狼疮队列在大流行期间与医生互动的最常用方法。平均有62.70％的医疗服务中断一年。超过三分之一的人出现了疾病发作，15%的人获得了COVID-19，但85%以上的人的结果良好。尽管大流行带来了挑战，在我们的狼疮队列中,大多数能够继续治疗的患者均获得了良好的结局.
